Global Dry Eye Disease Market

Dry Eye Disease Market Size, Share, Growth Analysis, By Product(Artificial Tears, Anti-inflammatory Drugs, Punctal Plugs, Secretagogues), By Distribution Channel(Hospital Pharmacies, Independent Pharmacies & Drug Stores, Online Pharmacies), By Region - Industry Forecast 2025-2032


Report ID: SQMIG35D2172 | Region: Global | Published Date: July, 2001
Pages: 157 | Tables: 65 | Figures: 75

Dry Eye Disease Market Dynamics

Dry Eye Disease Market Driver

Increased Prevalence of Dry Eye Disease to Supplement Market Growth

  • Dry eye disease, also known as keratoconjunctivitis sicca (KCS), is a common ophthalmic disorder that affects about 360 million people worldwide. Patients complain of dryness, irritation, redness, fatigue, and blurred vision. The prevalence varies with age, but it is increasing in both the young and old populations due to increased screen time, poor diet, increased use of contact lenses, and an increase in the number of LASIK surgeries. The ability of the lachrymal glands to produce tears decreases with age, resulting in dry eyes. One of the key factors contributing to the growth of the global dry eye drugs market is the rising incidence of dry eye disease due to an ageing population.

Dry Eye Disease Market Restraints

Limited Awareness Limit Market Growth

  • The general public is unaware of the importance of eye health. Many dry eye symptoms are misunderstood and can be easily treated or corrected with proper diagnosis and medications. People do not visit ophthalmologists on a regular basis unless they are experiencing severe symptoms. Dry eye symptoms such as redness, burning, and so on are frequently ignored and underdiagnosed, reducing the patient pool that can be treated with prescription drugs. According to a survey conducted in the United Kingdom, one out of every four adults does not have their eyes tested every two years as recommended by the NHS, with children having a higher level of ignorance about eye health.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Dry Eye Disease Market size was valued at USD 5.13 billion in 2019 and is poised to grow from USD 5.53 billion in 2023 to USD 10.92 billion by 2031, growing at a CAGR of 7.85% in the forecast period (2024-2031).

The market for dry eye disease is moderately competitive. In terms of market share, the market is currently dominated by a few major players. With the growing geriatric population and high disease prevalence, a few new smaller players are expected to enter the market in the coming years. AbbVie Inc. (Allergan PLC), Alcon Inc., and Santen Pharmaceutical Co. are among the market's major players. 'Allergan plc (now part of AbbVie Inc.)', 'Novartis AG', 'Santen Pharmaceutical Co., Ltd.', 'Johnson & Johnson', 'Otsuka Pharmaceutical Co., Ltd.', 'Shire (now part of Takeda Pharmaceutical Company Limited)', 'Sun Pharmaceutical Industries Ltd.', 'Bausch Health Companies Inc.', 'Alcon Inc. (a subsidiary of Novartis AG)', 'AbbVie Inc.', 'Akorn, Inc.', 'Nicox SA', 'Mitotech S.A.', 'Tarsus Pharmaceuticals, Inc.', 'Kala Pharmaceuticals, Inc.', 'Novaliq GmbH', 'Oyster Point Pharma, Inc.', 'AFT Pharmaceuticals Ltd.', 'OcuSoft, Inc.', 'Eyenovia, Inc.'

Dry eye disease, also known as keratoconjunctivitis sicca (KCS), is a common ophthalmic disorder that affects about 360 million people worldwide. Patients complain of dryness, irritation, redness, fatigue, and blurred vision. The prevalence varies with age, but it is increasing in both the young and old populations due to increased screen time, poor diet, increased use of contact lenses, and an increase in the number of LASIK surgeries. The ability of the lachrymal glands to produce tears decreases with age, resulting in dry eyes. One of the key factors contributing to the growth of the dry eye drugs market is the rising incidence of dry eye disease due to an ageing population.

One of the leading market trends in the dry eye disease market has been an increase in R&D spending, successful clinical trials, and increased new product approvals. A large number of companies are involved in clinical trials, such as Aldeyra Therapeutics, Inc.'s pipeline candidate Reproxalap, which is currently in Phase - III. This type of initiative is expected to drive the dry eye disease treatment market's revenue generation.

The dry eye disease market is studied on the basis of geography as North America, Europe, Asia-Pacific, South America, and Middle East & Africa. Due to the high prevalence of dry eye diseases and the ease with which solutions are available in the region, North America is expected to hold a significant share of the dry eye disease market. In this multi-screen world, people of all ages can be found. Computer or digital screen use may result in less blinking, which may contribute to symptoms of dry eye disease (DED), thereby increasing the demand for better and more effective DED therapeutics, which is expected to fuel growth in the North American region studied.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Dry Eye Disease Market

Report ID: SQMIG35D2172

$5,300
BUY NOW GET FREE SAMPLE